Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Page 1
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise RA, Naya IP, Singh D. Han MK, et al. Among authors: lomas da. ERJ Open Res. 2021 Mar 8;7(1):00663-2020. doi: 10.1183/23120541.00663-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33718490 Free PMC article.
FF/UMEC/VI significantly reduced CID risk versus dual therapies (all p<0.001). CONCLUSIONS: Prevention of short-term disease worsening was associated with better long-term clinical outcomes. FF/UMEC/VI reduced CID risk versus dual therapies; this effect may impro …
FF/UMEC/VI significantly reduced CID risk versus dual therapies (all p<0.001). CONCLUSIONS: Prevention of short-term disease worse …
Susceptibility to chronic mucus hypersecretion, a genome wide association study.
Dijkstra AE, Smolonska J, van den Berge M, Wijmenga C, Zanen P, Luinge MA, Platteel M, Lammers JW, Dahlback M, Tosh K, Hiemstra PS, Sterk PJ, Spira A, Vestbo J, Nordestgaard BG, Benn M, Nielsen SF, Dahl M, Verschuren WM, Picavet HS, Smit HA, Owsijewitsch M, Kauczor HU, de Koning HJ, Nizankowska-Mogilnicka E, Mejza F, Nastalek P, van Diemen CC, Cho MH, Silverman EK, Crapo JD, Beaty TH, Lomas DA, Bakke P, Gulsvik A, Bossé Y, Obeidat M, Loth DW, Lahousse L, Rivadeneira F, Uitterlinden AG, Hofman A, Stricker BH, Brusselle GG, van Duijn CM, Brouwer U, Koppelman GH, Vonk JM, Nawijn MC, Groen HJ, Timens W, Boezen HM, Postma DS; LifeLines Cohort study. Dijkstra AE, et al. Among authors: lomas da. PLoS One. 2014 Apr 8;9(4):e91621. doi: 10.1371/journal.pone.0091621. eCollection 2014. PLoS One. 2014. PMID: 24714607 Free PMC article.
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR. Schmid ST, et al. Among authors: lomas da. Int J Chron Obstruct Pulmon Dis. 2012;7:687-96. doi: 10.2147/COPD.S34560. Epub 2012 Sep 28. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 23055718 Free PMC article.
BACKGROUND: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is to raise the levels of AAT in patients with protease inhibitor phenotype ZZ (Glu342Lys)-inherited AAT deficiency and to protect lung tissues from proteolysis and progression of emph …
BACKGROUND: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is to raise the levels of AAT in patients wi …